Video

Dr. Saint Fleur-Lominy on the Role of Transplant in MPNs

Shella Saint Fleur-Lominy, MD, PhD, discusses the role of transplant in myeloproliferative neoplasms.

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health’s Perlmutter Cancer Center, discusses the role of transplant in myeloproliferative neoplasms (MPNs).

Currently, allogeneic stem cell transplant (allo-SCT) is the only curative option for patients with MPNs, says Saint Fleur-Lominy. JAK2 inhibitors can aid in symptom management to make patients more comfortable. Although there is some evidence that ruxolitinib (Jakafi) may also improve survival, the agent does not have a good disease-modifying effect.

Allo-SCT may be considered for patients with intermediate- or high-risk MPNs who don’t have significant comorbidities, says Saint Fleur-Lominy. The age of the patient could also influence transplant eligibility.

Eligible patients should be considered for transplant upfront, after which a JAK inhibitor can be considered upon relapse or progression. If a patient is asymptomatic, they can defer transplant until they develop symptoms, concludes Saint Fleur-Lominy.

Related Videos
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Andrew Davis, MD
Noa Biran, MD